---
title: "Qyuns Therapeutics Co., Ltd. Class H (2509) Gets a Buy from CICC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281676473.md"
description: "In a report released yesterday, from CICC maintained a Buy rating on Qyuns Therapeutics Co., Ltd. Class H, with a price target of HK$33.00.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qyuns Therapeutics Co., Ltd. Class H with a HK$31.58 average price target."
datetime: "2026-04-04T05:55:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281676473.md)
  - [en](https://longbridge.com/en/news/281676473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281676473.md)
---

# Qyuns Therapeutics Co., Ltd. Class H (2509) Gets a Buy from CICC

In a report released yesterday, from CICC maintained a Buy rating on Qyuns Therapeutics Co., Ltd. Class H, with a price target of HK$33.00.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qyuns Therapeutics Co., Ltd. Class H with a HK$31.58 average price target.

### Related Stocks

- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [02509.HK](https://longbridge.com/en/quote/02509.HK.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)

## Related News & Research

- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Yubico issues 1,430,000 class C shares for LTI 2026 employee incentive plan](https://longbridge.com/en/news/286947181.md)
- [Prevas AGM adopts 2025 accounts, sets SEK 4 dividend for 2025](https://longbridge.com/en/news/286949607.md)
- [Maxim Group Sticks to Its Buy Rating for Newsmax Inc. Class B (NMAX)](https://longbridge.com/en/news/286573867.md)